Abstract
Treatment options for metastatic renal cell carcinoma (RCC) have been limited due to its resistance to chemotherapy and radiotherapy. Benefits from immunotherapeutic agents provide only a small subset of patients. During the past decade major advances have been made toward understanding the molecular basis of RCC development. Such acquired knowledge has offered unique opportunities for the development of molecular targeting agents. These agents are predominately small molecules or monoclonal antibodies that exert their action through modulation of protein activity or inhibition of amplified signals directly implicated in disease mechanism. To date, some of newly molecular targeted agents have entered advanced phases of clinical development, received marketing authorization by regulatory agencies and have opened a possibility of multiple treatment options. This article overviews current knowledge in RCC molecular pathology with recent clinical data, and discuss present strategies for future development of targeted therapies.
Keywords: Renal cell carcinoma, molecular targeting agents, hypoxia inducible factor, vascular endothelial growth factor, receptor tyrosine kinase inhibitors, sorafenib, sunitinib, temsirolimus
Current Pharmaceutical Design
Title: Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Volume: 14 Issue: 11
Author(s): Snezana K. Bjelogrlic, Sinisa Radulovic and Nada Babovic
Affiliation:
Keywords: Renal cell carcinoma, molecular targeting agents, hypoxia inducible factor, vascular endothelial growth factor, receptor tyrosine kinase inhibitors, sorafenib, sunitinib, temsirolimus
Abstract: Treatment options for metastatic renal cell carcinoma (RCC) have been limited due to its resistance to chemotherapy and radiotherapy. Benefits from immunotherapeutic agents provide only a small subset of patients. During the past decade major advances have been made toward understanding the molecular basis of RCC development. Such acquired knowledge has offered unique opportunities for the development of molecular targeting agents. These agents are predominately small molecules or monoclonal antibodies that exert their action through modulation of protein activity or inhibition of amplified signals directly implicated in disease mechanism. To date, some of newly molecular targeted agents have entered advanced phases of clinical development, received marketing authorization by regulatory agencies and have opened a possibility of multiple treatment options. This article overviews current knowledge in RCC molecular pathology with recent clinical data, and discuss present strategies for future development of targeted therapies.
Export Options
About this article
Cite this article as:
Bjelogrlic K. Snezana, Radulovic Sinisa and Babovic Nada, Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives, Current Pharmaceutical Design 2008; 14 (11) . https://dx.doi.org/10.2174/138161208784246252
DOI https://dx.doi.org/10.2174/138161208784246252 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Epigenetic Targets in Lymphoproliferative Disorders
Current Cancer Drug Targets Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Clustering Algorithms: On Learning, Validation, Performance, and Applications to Genomics
Current Genomics Antisense Strategies
Current Molecular Medicine Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine Drug-Membrane Interactions: Significance for Medicinal Chemistry
Current Medicinal Chemistry Delivery of Therapeutics and Molecules Using Self-Assembled Peptides
Current Medicinal Chemistry Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands
Current Topics in Medicinal Chemistry Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Staurosporine Analogues from Microbial and Synthetic Sources and Their Biological Activities
Current Medicinal Chemistry Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Non-Melanoma Skin Cancer – Overview
Current Cancer Therapy Reviews Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients
Current Vascular Pharmacology